Serotonergic hallucinogens as translational models relevant to schizophrenia
Adam L. Halberstadt, Mark A. Geyer
The International Journal of Neuropsychopharmacology August 13, 2013 DOI: 10.1017/s1461145713000722 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | LSD Mescaline Psilocybin Serotonin |
| Keywords | Hallucinogen Schizophrenia object-oriented programming Neurochemical Psychosis Receptor |
| Citations | 66 |
| Key findings | Animal models of schizophrenia based on serotonergic hallucinogens have yielded insights into the linkage between 5-HT and schizophrenia and identified receptor targets for new therapeutic agents. |
Abstract
Abstract One of the oldest models of schizophrenia is based on the effects of serotonergic hallucinogens such as mescaline, psilocybin, and (+)-lysergic acid diethylamide (LSD), which act through the serotonin 5-HT2A receptor. These compounds produce a ‘model psychosis’ in normal individuals that resembles at least some of the positive symptoms of schizophrenia. Based on these similarities, and because evidence has emerged that the serotonergic system plays a role in the pathogenesis of schizophrenia in some patients, animal models relevant to schizophrenia have been developed based on hallucinogen effects. Here we review the behavioural effects of hallucinogens in four of those models, the receptor and neurochemical mechanisms for the effects and their translational relevance. Despite the difficulty of modelling hallucinogen effects in nonverbal species, animal models of schizophrenia based on hallucinogens have yielded important insights into the linkage between 5-HT and schizophrenia and have helped to identify receptor targets and interactions that could be exploited in the development of new therapeutic agents.
Comparable studies
Other narrative reviews on serotonin, most cited first.
Citations in the library
Cited by 39
- Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics May 1, 2019
- Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects Biological Psychiatry November 29, 2014
- Legal highs: staying on top of the flood of novel psychoactive substances Therapeutic Advances in Psychopharmacology January 26, 2015
- Dimensions of consciousness and the psychedelic state Neuroscience of Consciousness 2018
- Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission Proceedings of the National Academy of Sciences January 25, 2021
and 34 more in the library
Cites 42
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans Pharmacopsychiatry July 1, 1998
- Serotonin research: contributions to understanding psychoses TIPS - Trends in Pharmacological Sciences August 1, 2008
- Effects of psilocybin on time perception and temporal control of behaviour in humans Journal of Psychopharmacology May 20, 2006
and 37 more in the library